Sector News

Japan’s Otsuka to buy Avanir for $3.5 billion ahead of patent cliff

December 2, 2014
Life sciences
(Reuters) – Japanese drugmaker Otsuka Holdings Co Ltd plans to buy U.S.-based Avanir Pharmaceuticals Inc for about $3.5 billion to expand its neurologic drug portfolio ahead of an expiration of a key drug patent.
 
Otsuka said subsidiary Otsuka Pharmaceutical Co Ltd would pay $17 per share in cash, or a premium of 13.3 percent to Avanir’s closing price on Monday.
 
The deal, Otsuka’s biggest according to Thomson Reuters data, comes as the company aims to beef up its product pipeline ahead of a so-called “patent cliff” after April 2015, when its U.S. patent for schizophrenia drug Abilify expires and opens the way to generic competition.
 
Its global sales of Abilify totaled 575.7 billion yen ($5 billion) in the last fiscal year, around 40 percent of the total for Otsuka Holdings. The United States is the biggest market for the drug.
 
Japanese companies, helped by cash-rich balance sheets and encouraged by an ageing domestic population, are looking overseas for growth.
 
Otsuka will launch a tender offer within 10 business days to purchase all outstanding shares of Avanir, the companies said. The deal is expected to close in the first quarter of 2015.
 
Otsuka Pharmaceutical President Taro Iwamoto said the deal would “bring together Otsuka’s experience and business track record in the area of mental illnesses with Avanir’s strengths in neurologic diseases”, according to a statement.
 
Avanir developed Nuedexta, which treats pseudobulbar affect, a neurological disorder characterized by involuntary outbursts of crying or laughter.
 
But it failed to win approval from the U.S. Food and Drug Administration for a migraine drug device in November, a few weeks after the regulator had raised questions regarding some data submitted as part of the marketing application.
 
After the deal, Avanir will operate as a unit of Otsuka America Inc and will partner with Otsuka to enhance its development and marketing efforts in central nervous system-related disorders.
 
Goldman Sachs advised Otsuka, while Centerview Partners advised Avanir.
 
(1 US dollar = 118.8800 Japanese yen)
 
(Reporting by Ritsuko Ando in Tokyo and Neha Dimri in Bengaluru; Editing by Gopakumar Warrier and Jane Baird)

Related News

March 6, 2021

Takeda takes full control of drug for rare epilepsies

Life sciences

The deal inked with New York-based Ovid Therapeutics carries an almost $200 million upfront payment and could be worth as much as $856 million provided the medicine, known as soticlestat, hits certain milestones. 

March 6, 2021

Novartis signs Covid-19 vaccine manufacturing agreement with CureVac

Life sciences

Novartis has entered an initial agreement to manufacture the mRNA and bulk drug product for CureVac’s Covid-19 vaccine candidate, CVnCoV.

March 6, 2021

Disney teams with Philips to bring its characters to pediatric imaging

Life sciences

A whole new world: Philips and the Walt Disney Company will use animated shorts featuring some of Disney’s most famous characters in customized stories created with clinical guidance from Philips.

Send this to a friend